Morning Overview on MSN
The FDA cleared Xocova, the first oral antiviral to prevent COVID-19 after exposure, in a five-day pill course shown to cut infections in a phase 3 trial
Households where someone tests positive for COVID-19 now have an oral drug option to protect the people around them. The FDA ...
Video segment examines current Ebola outbreak concerns, unmet need surrounding the Bundibugyo strain and Ampligen’s previously published ...
"XOCOVA should be taken as soon as possible and within 72 hours following contact with an individual who has COVID‑19," Dr.
An arthritis drug reduces the amount of RSV in human respiratory cells, but experts say it's too early to say if it will ...
"James brings the right experience in the biopharma business as we’re accelerating the advancement of multiple clinical ...
The FDA has approved the oral antiviral Xocova (ensitrelvir) for postexposure prophylaxis of COVID-19 in adults and adolescents.
In a major expansion of the pandemic treatment toolkit, the U.S. Food and Drug Administration (FDA) has officially approved ...
Merck is in discussions with various global health authorities about making its COVID antiviral pill molnupiravir available ...
Japan's Shionogi & Co said on Monday the U.S. Food and Drug Administration has approved its oral antiviral Ensitrelvir, ...
The FDA approved the oral antiviral agent ensitrelvir (Xocova) to help prevent COVID-19 in people ages 12 years or older who ...
Shionogi Announces FDA Approval of XOCOVA®, the First and Only Oral Option to Help Prevent COVID-19 Following Exposure ...
After a prior misfire in demonstrating its protease inhibitor ensitrelvir’s potential as a COVID-19 treatment for U.S. patients, Shionogi has secured an FDA green light for the medicine in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results